Moderna, Inc. (MRNA) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets.
Analysis Summary
Moderna, Inc. reported revenue of $1.94B in the most recent fiscal year, growing at a 5-year CAGR of 19.3%.
Trailing-twelve-month margins: gross margin 55.3%, operating margin -158.1%, net margin -145.2%.
At the current price of $156.57, MRNA has negative trailing earnings (P/E not meaningful) and an ROE of -39.20%. Market capitalisation stands at $62.1B, placing it among large-cap names.
Balance sheet quality for MRNA: current ratio of 3.3, net cash position of $3.88B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $156.57 |
| Market Cap | $62.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.34 |
| EV / EBITDA | -20.01 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -39.20% |
| Return on Invested Capital | -39.16% |
| Return on Assets | -28.75% |
| Gross Margin | 55.35% |
| Operating Margin | -158.13% |
| Net Margin | -145.16% |
Financial Health
| Debt / Equity | 0.22 |
| Current Ratio | 3.29 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.46 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| BBIO | BridgeBio Pharma, Inc. | $13.4B | 35.1% | ||
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.2B | 29.72 | -56.6% | |
| EXEL | Exelixis, Inc. | $14.4B | 17.29 | 7.74 | |
| BMRN | BioMarin Pharmaceutical Inc. | $12.7B | 170.34 | 1.98 | 1.2% |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| CAI | Caris Life Sciences, Inc. | $8.0B | 85.99 | 15.29 | 18.8% |
Price Performance
| 1 month | +131.29% |
| 3 months | +127.67% |
| Year-to-date | +393.79% |
| 1 year | +482.48% |
| 3 years | +39.83% |
52-Week Range
| 52-week High | $176.66 |
| 52-week Low | $22.28 |
| Avg Volume (90d) | 13.5M |
Related companies: BBIO · BMRN · CAI · EXEL · HALO · JAZZ · MDGL
Explore sector: Healthcare · Biotechnology
More sections of MRNA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks